Patents Examined by Scott Long
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11389485
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 19, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Binding proteins specific for RAS neoantigens and uses thereof
    Patent number: 11382954
    Abstract: The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: July 12, 2022
    Assignee: FRED HUTCHINSON CANCER CENTER
    Inventors: Rachel Perret, Philip D. Greenberg, Thomas M. Schmitt, Aude G. Chapuis, Ingunn M. Stromnes, Tijana Martinov
  • Recombinant oncolytic virus, synthetic DNA sequence, and application thereof
    Patent number: 11376290
    Abstract: A recombinant oncolytic virus, a synthetic DNA sequence and applications of the virus. The recombinant oncolytic virus includes a genome and an exogenous DNA sequence inserted in the genome. The exogenous DNA sequence adapts to express a basic peptide fragment, to increase the environmental pH in a host infected by the recombinant oncolytic virus. More than 60% of amino acids in the basic peptide fragment are basic amino acids. The recombinant oncolytic virus and the synthetic DNA sequence of the disclosure are used to prepare an anti-tumor drug.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: July 5, 2022
    Assignee: WUHAN BOWEID BIOTECHNOLOGY CO., LTD.
    Inventor: Ligang Cai
  • Platform for enhanced targeted delivery
    Patent number: 11376332
    Abstract: Embodiments of the disclosure concern methods and compositions for delivering therapeutic, diagnostic or interventional moieties, such as complex and simple entities such as biologies, including at least cells, for example. The methods employ targeted delivery by employing at least one ALCAM-binding moiety on the therapeutic, diagnostic or interventional moiety to be delivered. In specific cases, the ALCAM-binding moiety is present on or with the therapeutic moiety in multiple iterations. In certain embodiments, the ALCAM-binding moiety comprises at least one SRCR domain from CD6 and a stalk, such as from CD6, of the secretable or molecular form thereof.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 5, 2022
    Assignee: Baylor College of Medicine
    Inventors: Nabil M. Ahmed, Hebatalla S. Samaha, Antonella Pignata, Kristen Fousek
  • LMP1-expressing cells and methods of use thereof
    Patent number: 11369635
    Abstract: The disclosure provides immunogenic cells expressing LMP1, and use thereof in activating T cells and treating cancer. Also provided are methods of producing the immunogenic cells.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: June 28, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Baochun Zhang, Il-Kyu Choi, Zhe Wang
  • Recombinant erIL-15 NK cells
    Patent number: 11364265
    Abstract: Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: June 21, 2022
    Assignees: NantCell, Inc., NantBio, Inc., ImmunityBio, Inc.
    Inventors: Patrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi, Hans G. Klingemann
  • Anticancer composition comprising tumor-specific oncolytic adenovirus and immune checkpoint inhibitor
    Patent number: 11364272
    Abstract: The present invention relates to an anticancer composition comprising a tumor-specific oncolytic adenovirus and an immune checkpoint inhibitor. The recombinant adenovirus having IL-12 and shVEGF, or IL-12 and GM-CSF-RLX inserted therein, according to the present invention, exhibits an excellent anticancer effect by enhancing immune functions, and such anticancer effect has been confirmed to be notably enhanced through concomitant administration with an immune checkpoint inhibitor, and thus the present invention may be used as a key technique in the field of cancer treatment.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: June 21, 2022
    Assignee: GENEMEDICINE CO., LTD.
    Inventors: Chae Ok Yun, Hyo Min Ahn
  • MRNA functionalization method
    Patent number: 11364259
    Abstract: The present invention provides a functionalized mRNA including mRNA and double-stranded RNA including at least one RNA oligomer hybridized with mRNA. Functionalized mRNA is provided according to this configuration.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: June 21, 2022
    Assignees: THE UNIVERSITY OF TOKYO, KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION
    Inventors: Satoshi Uchida, Keiji Itaka, Kazunori Kataoka, Naoto Yoshinaga
  • Methods for targeted insertion of DNA in genes
    Patent number: 11365407
    Abstract: Methods and compositions for modifying the coding sequence of endogenous genes using rare-cutting endonucleases and transposases. The methods and compositions described herein can be used to modify the coding sequence of endogenous genes.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: June 21, 2022
    Assignee: BLUEALLELE CORPORATION
    Inventor: Nicholas J. Baltes
  • Application of oncolytic viruses as immunostimulants for treatment of tumors and/or cancers
    Patent number: 11357804
    Abstract: Provided is the use of selectively replicating oncolytic viruses in the preparation of immunostimulants for treatment of tumors and/or cancers, wherein the oncolytic viruses do not carry exogenous immunoregulatory genes.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: June 14, 2022
    Assignee: HANGZHOU CONVERD CO., LTD.
    Inventors: Ronghua Zhao, Yanjun Zheng, Fang Hu
  • Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
    Patent number: 11357841
    Abstract: Methods of expanding tumor infiltrating lymphocytes (TILs) using a potassium channel agonist, such as a KCa3.1 (IK channel) agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: June 14, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Krit Ritthipichai, Michael T. Lotze
  • Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
    Patent number: 11357799
    Abstract: Described herein are compositions and techniques related to generation and therapeutic application of cardiosphere-derived cells (CDCs) and CDC-derived exosomes. These cells and their secreted vesicles contain a unique milieu of biological factors, including cytokines, growth factors, transcription factors, nucleic acids including non-coding nucleic acids such as microRNAs, that serve to initiate and promote many therapeutic effects. Exosomes and their “cargo” contents, such as microRNAs can favorably modulate apoptosis, inflammation and fibrosis in the injured heart. Thus, CDC-derived exosomes represent a novel “cell-free” therapeutic candidate for tissue repair.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 14, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Eduardo Marban, Mark Amin Aminzadeh
  • Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer
    Patent number: 11351209
    Abstract: The present invention provides a composition comprising a phosphatidylinositol 3-kinase (PI3K) inhibitor and a modified virus for separate, subsequent or simultaneous use in the treatment of cancer, wherein the modified virus is for intravenous administration.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: June 7, 2022
    Assignee: Queen Mary University of London
    Inventors: Yaohe Wang, Mark Ferguson, Nicholas R. Lemoine
  • Car+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
    Patent number: 11344577
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf” treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: May 31, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J. Neil Cooper, Hiroki Torikai
  • Immune cells expressing engineered antigen receptors
    Patent number: 11344578
    Abstract: Provided herein are immune cells expressing antigenic receptors, such as a chimeric antigen receptor and a T cell receptor. Further provided herein are methods of treating immune-related disorder by administering the antigen-specific immune cells.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: May 31, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Katy Rezvani, Elizabeth J. Shpall
  • Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
    Patent number: 11345891
    Abstract: The present disclosure relates to compositions, nucleic acid constructs, methods and kits thereof for cell induction or reprogramming cells to the dendritic cell state or antigen presenting cell state, based, in part, on the surprisingly effect described herein of novel use and combinations of transcription factors that permit induction or reprogramming of differentiated or undifferentiated cells into dendritic cells or antigen presenting cells. Such compositions, nucleic acid constructs, methods and kits can be used for inducing dendritic cells in vitro, ex vivo, or in vivo, and these induced dendritic cells or antigen presenting cells can be used for immunotherapy applications.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 31, 2022
    Assignee: Asgard Therapeutics AB
    Inventors: Carlos Filipe Ribeiro Lemos Pereira, Cristiana Ferreira Pires, Fabio Alexandre Fiuza Rosa
  • Engineered viral vector reduces induction of inflammatory and immune responses
    Patent number: 11339396
    Abstract: Modified viral genomes are able to reduce induction of inflammatory and immune anti-viral responses. This manifests itself in reduced NF-kB activity, increased viral transduction rates, and increased expression of transgenes. Viral genomes are modified by incorporating one or more oligonucleotide sequences which are able to bind to TLR9 but not induce activation of it. The oligonucleotide sequences may be synthetic, bacterial, human, or from any other source.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: May 24, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Ying Kai Chan, George M. Church
  • Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using LGR4, LGR5 and LGR6 expressing epithelial stem cells
    Patent number: 11338060
    Abstract: Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: May 24, 2022
    Assignee: PolarityTE, Inc
    Inventor: Denver M. Lough
  • Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
    Patent number: 11339200
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: May 24, 2022
    Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
    Inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Wei Zhu, Xin Yao, Zhiyuan Li, Li Zhang, Lin Zhu, Anyun Ma, Yutian Wei, Yanfeng Li, Qingxia Wang, Jiaping He
  • Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cell
    Patent number: 11337922
    Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: May 24, 2022
    Assignees: BioN Tech SE, Tron—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg Universität Mainz GmbH
    Inventors: Hossam Hefesha, Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Walzer